Cytomx Thera (CTMX) Stock Price, Quote & News

Company Profile

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index f...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 515 3185

Fax: 650 351 0353

Website: www.cytomx.com

Address:

151 Oyster Point Boulevard, Suite 400, South San Francisco, United States

NeonDeon Sep. 8 at 9:51 PM

$CTMX Big money here.. I know some of them.,

1 · Reply

limitlist Sep. 8 at 7:40 PM

$CTMX taking a small position

0 · Reply

SofaKing_Nuts Sep. 8 at 2:24 PM

$CTMX shorts are clowns 🤡

0 · Reply

SmartMoneyWins Sep. 6 at 7:08 PM

SKYQ is the ticker that should be on everyone's top list! This will be the next penny to go big! "Sky Quarry Announces Strategic Digital Asset Initiative." -Strategic expansion into digital assets to diversify company's treasury holdings. -Early mover advantage in energy sector's digital assets adoption. -Potential to create a new revenue streams through blockchain integration Make sure you get SKYQ and lets bank on it. $CTMX $EVAX $LGHL $JEM Good runs.

1 · Reply

anotherdip Sep. 6 at 12:23 PM

$CTMX 165m shares outstanding, 133m held by institutions, just saying..12 new over 1m shares in 2nd Quarter https://13f.info/cusip/23284F105/2025/2/compare/2025/1

0 · Reply

Chartist0_0 Sep. 5 at 8:35 PM

$CTMX bull flag break out. 4$ incoming

0 · Reply

Gator5326 Sep. 5 at 7:01 PM

$CTMX CEO told us what’s coming yesterday. 😎

1 · Reply

anotherdip Sep. 5 at 6:18 PM

$CTMX nice 820,000 share buy

0 · Reply

Rick2058 Sep. 4 at 3:00 PM

$CTMX Americanbulls signal update BUY confirmed 9/3...Market Outlook *The bulls have compelling evidence supporting their stance, prompting us to consider placing a bullish bet. Today’s candlestick has a white body and its close is above the confirmation level. The bullish pattern that was previously identified is finally confirmed and a BUY signal is generated. Now may be the opportune moment to join this upswing and capitalize on the bullish market sentiment. The market is signaling a potential new profit opportunity. Don't let this opportunity slip through your fingers*

0 · Reply

bryantboy99 Sep. 4 at 1:33 PM

$CTMX You can listen to a replay of the Cantor Global Healthcare conference. https://ir.cytomx.com/events-and-presentations

0 · Reply

CytomX Therapeutics to Present at Upcoming September Investor Conferences

Aug 13, 2025, 8:00 AM EDT - 26 days ago

CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study

Aug 8, 2025, 6:10 PM EDT - 4 weeks ago

CytomX Therapeutics, Inc. (CTMX) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 5:05 PM EDT - 4 weeks ago

CytomX Therapeutics: Updated Outlook For Late 2025

Aug 7, 2025, 4:10 PM EDT - 4 weeks ago

CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 8:00 AM EDT - 5 weeks ago

CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025

May 29, 2025, 8:00 AM EDT - 3 months ago

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

May 19, 2025, 8:00 AM EDT - 4 months ago

CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma

May 13, 2025, 10:34 AM EDT - 4 months ago

CytomX Therapeutics: Doubling Overnight On Phase 1 Data

May 12, 2025, 2:40 PM EDT - 4 months ago

CytomX Therapeutics, Inc. (CTMX) CX-2051 Phase 1 Interim Clinical Data Call (Transcript)

May 12, 2025, 11:11 AM EDT - 4 months ago

Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report

May 12, 2025, 6:50 AM EDT - 4 months ago

CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

May 12, 2025, 6:15 AM EDT - 4 months ago

CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)

May 12, 2025, 6:15 AM EDT - 4 months ago

CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 8:00 AM EDT - 4 months ago

CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025

Apr 28, 2025, 4:00 PM EDT - 4 months ago

CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting

Mar 6, 2025, 6:34 PM EST - 6 months ago

CytomX Therapeutics, Inc. (CTMX) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 4:10 PM EST - 6 months ago

CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update

Mar 5, 2025, 8:00 AM EST - 6 months ago

CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference

Feb 27, 2025, 8:00 AM EST - 6 months ago

CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Jan 6, 2025, 4:05 PM EST - 8 months ago

CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update

Nov 27, 2024, 8:00 AM EST - 10 months ago

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Nov 8, 2024, 8:44 AM EST - 10 months ago

CytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:10 PM EST - 10 months ago

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Sep 9, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

Aug 8, 2024, 4:10 PM EDT - 1 year ago

CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 18, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Jun 17, 2024, 4:15 PM EDT - 1 year ago

CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

May 16, 2024, 4:15 PM EDT - 1 year ago

CytomX Therapeutics Announces New Employment Inducement Grants

May 9, 2024, 9:10 AM EDT - 1 year ago

CytomX stock down 30% despite encouraging cancer study results

May 8, 2024, 4:10 PM EDT - 1 year ago

CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024, 4:10 PM EDT - 1 year ago

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

May 7, 2024, 4:15 PM EDT - 1 year ago

CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)

May 1, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024

Apr 25, 2024, 6:33 PM EDT - 1 year ago

CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town

Apr 8, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors

Apr 3, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

Mar 21, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

Mar 18, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

Mar 11, 2024, 6:39 PM EDT - 1 year ago

CytomX Therapeutics, Inc. (CTMX) Q4 2023 Earnings Call Transcript

Mar 11, 2024, 4:10 PM EDT - 1 year ago

CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update

Mar 4, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024

Feb 27, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics to Present at Upcoming March Investor Conferences

Jan 24, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b

Jan 12, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference

Jan 4, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics Outlines 2024 Company Priorities and Milestones

Dec 21, 2023, 8:00 AM EST - 1 year ago

CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 8, 2023, 2:32 AM EST - 1 year ago

CytomX Therapeutics, Inc. (CTMX) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:15 PM EST - 1 year ago

CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 1, 2023, 8:00 AM EDT - 2 years ago

CytomX Therapeutics to Present at Upcoming November Investor Conferences

NeonDeon Sep. 8 at 9:51 PM

$CTMX Big money here.. I know some of them.,

1 · Reply

limitlist Sep. 8 at 7:40 PM

$CTMX taking a small position

0 · Reply

SofaKing_Nuts Sep. 8 at 2:24 PM

$CTMX shorts are clowns 🤡

0 · Reply

SmartMoneyWins Sep. 6 at 7:08 PM

1 · Reply

anotherdip Sep. 6 at 12:23 PM

$CTMX 165m shares outstanding, 133m held by institutions, just saying..12 new over 1m shares in 2nd Quarter https://13f.info/cusip/23284F105/2025/2/compare/2025/1

0 · Reply

Chartist0_0 Sep. 5 at 8:35 PM

$CTMX bull flag break out. 4$ incoming

0 · Reply

Gator5326 Sep. 5 at 7:01 PM

$CTMX CEO told us what’s coming yesterday. 😎

1 · Reply

anotherdip Sep. 5 at 6:18 PM

$CTMX nice 820,000 share buy

0 · Reply

Rick2058 Sep. 4 at 3:00 PM

0 · Reply

bryantboy99 Sep. 4 at 1:33 PM

$CTMX You can listen to a replay of the Cantor Global Healthcare conference. https://ir.cytomx.com/events-and-presentations

0 · Reply

Hamelot Sep. 4 at 1:23 PM

$CTMX $0.60 cost basis and holding forever. Happy to be as patient as needed 😴

0 · Reply

Gator5326 Sep. 4 at 1:03 PM

$CTMX “Clear proof of concept” 😎😎😎

0 · Reply

Gator5326 Sep. 4 at 1:02 PM

$CTMX Partnership interest! 😎😎

0 · Reply

bryantboy99 Sep. 4 at 1:02 PM

$CTMX "Robust interest in our data from multiple parties over the last few months"!!!

1 · Reply

Bionco Sep. 3 at 5:48 PM

$CTMX my three babies, $ACRS, $VTYX and $CTMX, all are and will be doing well in the long run!

1 · Reply

ace_10 Sep. 2 at 2:00 PM

$CTMX when will this start moving up??

1 · Reply

MonteCarrlo Aug. 29 at 7:43 PM

$CTMX ouch!!! 😂😂😂🤡

0 · Reply

lidopete Aug. 28 at 12:50 PM

$CTMX NEWS RELEASE https://ir.cytomx.com/news-releases/news-release-details/cytomx-therapeutics-present-upcoming-september-investor-1

0 · Reply

lidopete Aug. 28 at 12:49 PM

$CTMX https://ir.cytomx.com/news-releases/news-release-details/cytomx-therapeutics-present-upcoming-september-investor-1

0 · Reply

anotherdip Aug. 27 at 5:03 PM

$CTMX Feb 20 $2 calls are between .65-.70 , that's a good sign, I wanted to buy more, but little to pricey

0 · Reply

Rick2058 Aug. 27 at 1:40 PM

$CTMX Barchart on radar for Tops Stocks Under $10 (#2)

0 · Reply

Rick2058 Aug. 26 at 5:03 PM

$CTMX Barchart on radar for Tops Stocks Under $10 (#4)

0 · Reply

Market Cap	376.00M
Revenue (ttm)	138.10M
Net Income (ttm)	31.87M
EPS (ttm)	N/A
PE Ratio	3.75
Forward PE	31.82
Profit Margin	23.08%
Debt to Equity Ratio	0.00

Volume	3,414,900
Avg Vol	2,590,828
Day's Range	N/A - N/A
Shares Out	164.91M
Stochastic %K	61%
Beta	2.18
Analysts	Strong Sell
Price Target	$5.75